Home
Scholarly Works
1045 Phase II trial of the multi-targeted...
Journal article

1045 Phase II trial of the multi-targeted antifolate LY231514 (MTA) as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC)

Authors

Rusthoven J; Eisenhauer E; Butts C; Gregg R; Dancey J; Fisher B; Iglesias J

Journal

European Journal of Cancer, Vol. 33, ,

Publisher

Elsevier

Publication Date

September 1, 1997

DOI

10.1016/s0959-8049(97)85830-3

ISSN

0959-8049

Contact the Experts team